Registry of Fluzoparib for Ovarian Cancer Treatment
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
This study is testing how well fluzoparib works and how safe it is for people with ovarian cancer in everyday settings.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 490 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05206890 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the safety and efficacy of fluzoparib in patients with ovarian cancer under real-world conditions. It aims to gather data on various subgroups of ovarian cancer patients to inform treatment approaches and assess the pharmacoeconomic aspects of fluzoparib. The study includes patients diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are eligible for fluzoparib therapy. By analyzing real-world outcomes, the study seeks to enhance understanding of treatment effectiveness and patient management.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 and older diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Not a fit: Patients who are pregnant or lactating, or those participating in other interventional studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of fluzoparib, potentially leading to improved treatment strategies for ovarian cancer patients.
How similar studies have performed: Other studies involving PARP inhibitors have shown promising results in improving outcomes for ovarian cancer patients, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Sign informed consent and voluntarily join the study; 2. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology; 3. ≥ 18 years old; 4. The investigator determined that the patient could receive fluzoparib monotherapy or combination therapy; 5. For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of fluzoparib Exclusion Criteria: 1. There is evidence that the patient is a pregnant or lactating woman; 2. Participating in any research with intervention measures other than routine clinical practice; 3. The researcher judges other situations that are not suitable for inclusion in the study;
Where this trial is running
Wuhan, Hubei
- Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.